{
    "nct_id": "NCT03742245",
    "official_title": "Multicenter Phase I/Ib Trial of Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer",
    "inclusion_criteria": "* Provision of informed consent prior to any study-specific procedures.\n* Female or male ≥18 years of age.\n* Histologically or cytologically confirmed relapsed/refractory and/or metastatic breast cancer with the exception of human epidermal growth factor receptor 2-positive breast cancer.\n* Evaluable or measurable disease as per the RECIST 1:1.\n* Normal organ and bone marrow function measured within 28 days prior to administration of the study treatment.\n* White blood cell (WBC) count >2,500/microL and <15,000/microL\n* Lymphocyte count ≥500/microL\n* Total bilirubin (TBL) ≤1.5 × institutional ULN\n* Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤2.5 × institutional ULN (patients with liver metastases ≤5 × ULN) and alkaline phosphatase (ALP) ≤2.5 × institutional ULN (patients with liver metastases ≤5 × ULN).\n* Serum creatinine ≤1.5 × ULN and creatinine clearance (CrCl) estimated using the Cockcroft-Gault equation of ≥51 mL/min\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Life expectancy ≥6 months.\n* Postmenopausal or evidence of non-childbearing status for women of childbearing potential (WOCBP): negative serum (beta-human chorionic gonadotropin) pregnancy test within 28 days of study treatment and confirmed prior to treatment on Day 1.\n* WOCBP must be willing to use 2 highly effective methods of contraception for the course of the study through 1 month after the last treatment dose.\n* Male patients must be willing to use condom contraception for the course of the study through 3 months after the last treatment dose.\n* Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.\n* Willing to undergo biopsy as required by the study.\n* Able to swallow pills and capsules\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).\n* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation.\n* Whole blood transfusions in the last 120 days prior to study entry.\n* Unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study treatment.\n* Concomitant use of known strong or moderate cytochrome P450 (CYP)3A inhibitors.\n* Concomitant use of known strong or moderate CYP3A inducers.\n* Persistent toxicities (CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.\n* Participants with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.\n* Known hypersensitivity to olaparib or vorinostat or any of their excipients or analogues (PARP/HDAC inhibitors).\n* Breastfeeding women.\n* No active malignancy except for non-melanoma skin cancer, in situ cervical cancer, or a treated cancer from which the patient has been continuously disease free for more than 5 years.\n* Pneumonitis or at risk of pneumonitis.\n* Uncontrolled brain or leptomeningeal metastases.\n* Any systemic chemotherapy or radiation therapy within 4 weeks prior to study entry.\n* Major surgery within 4 weeks of starting the study treatment.\n* Participation in another clinical study with an investigational product during the last 3 months.\n* Any previous treatment with PARP inhibitor including olaparib or HDAC inhibitor including vorinostat.\n* New York Heart Association Class III or IV heart failure or unstable angina.\n* History of liver disease, such as cirrhosis or active/chronic hepatitis B or C.\n* Sustained or clinically significant cardiac arrhythmias including sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block (Mobitz II or higher atrioventricular nodal block), prolonged corrected QT interval (mean >470 milliseconds), or history of acute myocardial infarction.\n* Risk factors for torsades de pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade atrioventricular nodal block.\n* Concomitant disease(s) that could prolong QT interval such as autonomic neuropathy (caused by diabetes or Parkinson's disease), human immunodeficiency virus (HIV), cirrhosis, uncontrolled hypothyroidism, or cardiac failure.\n* Concomitant medication(s) known to prolong QT interval (patient must be off the drug for 2 weeks to be eligible).\n* Presence of active or suspected acute or chronic uncontrolled infection or history of immunocompromise, including participants who are known to be serologically positive for HIV.\n* Any severe and/or uncontrolled medical conditions or other conditions that could affect study participation, such as severely impaired lung function; any active (acute or chronic) or uncontrolled infection/disorders; or non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study treatment.",
    "miscellaneous_criteria": ""
}